Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oxygen technique may improve safety during cancer diagnostic scopes

NCT ID NCT05696288

Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 160 people with head and neck cancer who needed a diagnostic scope (panendoscopy) under anesthesia. Researchers compared standard oxygen therapy with a high-flow system called THRIVE to see which one better prevents drops in oxygen levels. The goal is to find a safer way to deliver oxygen during this common procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Apr 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients suffering from a head and neck cancer, most often tumor of the bucco-pharyngo-laryngeal cavities, having to carry out a diagnostic HN panendoscopy; * Patient over 18 years of age; * ASA \< 4; * BMI ≤ 45; * Patient willing and able to provide written informed consent for the trial;; * Patient affiliated with a health insurance system. Exclusion Criteria: * Patient with a contraindication to the Optiflow™ system as defined in the manufacturer's brochure; * Patient with a tumor obstructing more than 80% of the glottic lumen; * Patient with impossible intubation criteria: * Mallampati 4 and mouth opening less than 20 mm * Retrognathia * Patient with: * A known intracranial pathology; * Documented pulmonary hypertension; * Uncontrolled epilepsy; * Uncontrolled heart rhythm disorder; * Pulmonary pathology with hypoxemia: Spo2 \<92% in ambient air; * Patient at high risk of a full stomach evaluated by the anesthetist; * ASA ≥ 4 * Morbid obesity with BMI\> 45; * Obstructive upper airway tumor with functional impact; * Known contraindication to propofol or alfentanil; * Panendoscopy procedure to be combined with an oesogastro-duodenal fibroscopy; * Vulnerable persons as defined by articles 64 and 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices : * In the case of incapacitated subjects who have not given, or have not refused to give, informed consent before the onset of their incapacity, a clinical investigation may be conducted only where, in addition to the conditions set out in Article 62(4) * Pregnant or breast-feeding women who do not fall under the provisions of Article 66 * Adults subject to a legal protection order or unable to give their consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.